Search results
Jump to navigation
Jump to search
Page title matches
- ...genetics">{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?term=Pharmacogenomics |title=Pharmacogenetics |accessdate=2008-01-22 |author=Anonymous |authorlin ...Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W |title=Potential role of pharmacogenomics in reducing drug-related side effects and adverse reactionss: a systematic5 KB (713 words) - 17:34, 10 February 2024
- 203 bytes (24 words) - 17:07, 14 May 2010
- 12 bytes (1 word) - 10:00, 23 January 2008
- Auto-populated based on [[Special:WhatLinksHere/Pharmacogenomics]]. Needs checking by a human.608 bytes (78 words) - 19:29, 11 January 2010
- 423 bytes (56 words) - 13:18, 24 July 2008
Page text matches
- #REDIRECT [[Pharmacogenomics]]30 bytes (2 words) - 12:04, 20 October 2008
- {{r|Pharmacogenomics}}444 bytes (50 words) - 18:32, 3 January 2009
- {{r|Pharmacogenomics}}506 bytes (63 words) - 01:21, 13 March 2009
- {{r|Pharmacogenomics}}472 bytes (60 words) - 17:02, 11 January 2010
- {{r|Pharmacogenomics}}471 bytes (60 words) - 07:38, 8 January 2010
- Auto-populated based on [[Special:WhatLinksHere/Pharmacogenomics]]. Needs checking by a human.608 bytes (78 words) - 19:29, 11 January 2010
- {{r|Pharmacogenomics}}926 bytes (114 words) - 15:48, 11 January 2010
- {{r|Pharmacogenomics}}2 KB (187 words) - 17:07, 11 January 2010
- ==Pharmacogenomics==5 KB (679 words) - 09:15, 29 August 2009
- ...genetics">{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?term=Pharmacogenomics |title=Pharmacogenetics |accessdate=2008-01-22 |author=Anonymous |authorlin ...Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W |title=Potential role of pharmacogenomics in reducing drug-related side effects and adverse reactionss: a systematic5 KB (713 words) - 17:34, 10 February 2024
- *[http://www.pharmgkb.org PharmGKB] — The Pharmacogenetics and Pharmacogenomics Knowledge Base, a resource for SNPs associated with drug response and dis2 KB (338 words) - 12:38, 29 January 2009
- ...olution, signal transduction pathways and networks, stress responses and [[pharmacogenomics]] in cancer biology. Members of the group explore the linkage between theor3 KB (389 words) - 02:20, 12 January 2011
- ...Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W| title=Potential role of pharmacogenomics in reducing drug-related side effects and adverse reactionss: a systematic3 KB (483 words) - 17:34, 10 February 2024
- ...ctive in their places of origin, the reasons for which may relate to the [[pharmacogenomics]] of the indigenous population.3 KB (421 words) - 22:32, 8 January 2009
- {{r|Pharmacogenomics}}4 KB (505 words) - 16:36, 11 January 2010
- ...Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W |title=Potential role of pharmacogenomics in reducing drug-related side effects and adverse reactionss: a systematic ...Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W |title=Potential role of pharmacogenomics in reducing drug-related side effects and adverse reactionss: a systematic20 KB (2,762 words) - 10:47, 20 May 2024
- ...h empirically delineated classes of unexplained chronic fatigue. | journal=Pharmacogenomics | year= 2006 | volume= 7 | issue= 3 | pages= 387-94 | pmid=16610949 ...ne effector and receptor genes predict chronic fatigue syndrome. | journal=Pharmacogenomics | year= 2006 | volume= 7 | issue= 3 | pages= 475-83 | pmid=1661095714 KB (1,974 words) - 11:52, 2 February 2023
- ...Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W |title=Potential role of pharmacogenomics in reducing drug-related side effects and adverse reactionss: a systematic6 KB (767 words) - 17:34, 10 February 2024
- ...Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W |title=Potential role of pharmacogenomics in reducing drug-related side effects and adverse reactionss: a systematic8 KB (1,130 words) - 17:34, 10 February 2024
- ====Pharmacogenomics==== ...ommon VKORC1 and GGCX polymorphisms associated with warfarin dose |journal=Pharmacogenomics J |volume=5 |pages=262-70 |year=2005 |pmid=15883587 }}</ref>: particular mu52 KB (7,136 words) - 22:53, 6 April 2014
- }}</ref> One review suggested [[pharmacogenomics]] may identify the patients likely to be harmed by coumadin. <ref>{{citatio | journal = Pharmacogenomics | date = 2007 Feb | volume = 8 | issue = 2 | pages = 151-821 KB (2,921 words) - 23:03, 22 May 2013
- {{main|Pharmacogenomics}} ...Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W |title=Potential role of pharmacogenomics in reducing drug-related side effects and adverse reactionss: a systematic39 KB (5,361 words) - 17:35, 10 February 2024
- ...load is associated with symptoms in chronic fatigue syndrome patients.] ''Pharmacogenomics'' 7:485-94. ...ests sleep and allostatic load involvement in chronic fatigue syndrome.] ''Pharmacogenomics'' 7:455-65.243 KB (35,084 words) - 07:35, 10 April 2024
- ...an to reach an accurate diagnosis faster. Another new branch of medicine [[pharmacogenomics]] is the product of breeding between [[information technology]] and [[biolo30 KB (4,318 words) - 11:09, 21 November 2020
- * [[Pharmacogenomics]]25 KB (3,396 words) - 13:29, 2 April 2024
- ...itle=Personalized therapy in pain management: where do we stand? | journal=Pharmacogenomics | year= 2010 | volume= 11 | issue= 6 | pages= 843-64 | pmid=20504256 | doi=42 KB (5,794 words) - 14:08, 2 February 2023
- ...http://content.nejm.org/cgi/content/full/351/20/2035}}</ref> Presumably, [[pharmacogenomics]] will lead to individualized drug treatment; until then the use of race ma73 KB (10,150 words) - 21:46, 20 August 2014
- ...Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W |title=Potential role of pharmacogenomics in reducing drug-related side effects and adverse reactionss: a systematic81 KB (10,863 words) - 17:35, 10 February 2024